Please login to the form below

Not currently logged in
Email:
Password:

Pfizer drives oncology R&D growth

Pfizer is to run seven new clinical studies into liver, renal cell carcinoma, lung and prostate cancers
Pfizer is to run seven new clinical studies into liver, renal cell carcinoma, lung and prostate cancers.

These studies are part of Pfizer's growing oncology research and development (R&D) programme, which has increased by 400 per cent since 2003. Dedicating just under a quarter of its overall R&D budget to oncology, the company currently has 22 compounds in 232 clinical studies.

"We are seeing our sustained efforts in oncology mature as our development programmes continue to advance into late-stage clinical trials," said Dr Charles Baum, vice-president of Pfizer Global Research and Development.

In 2008 alone, Pfizer has presented 299 new agents at the American Society of Clinical Oncology (ASCO) meeting. The company has also started two phase III studies and expects to start the remaining five by the end of the year.

A dedicated business unit, focused on oncology within Pfizer's worldwide pharmaceutical group, was established in March 2008. The unit will accelerate the launches of new oncology agents and focus research efforts on cancers common in Asia such as those of the liver, oesophagus and nasopharynx.

4th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics